A study published in September 2026 found that loss of function in ALDH3B2 led human pancreatic duct cells to take on beta-like features in laboratory experiments. The cells released insulin in response to glucose, and after transplantation into diabetic mice, they lowered blood glucose to near-normal levels for six weeks. The findings are preclinical; they do not demonstrate a treatment that works in people.
Pancreatic duct cells take on beta-like features
Researchers found that disrupting ALDH3B2 function could change the identity of cell-line-based and human pancreatic duct cells. The cells expressed more genes associated with pancreatic beta cells, which normally release insulin in response to glucose. They also secreted insulin when glucose was present.
The resulting cells were beta-like, rather than fully equivalent to natural human beta cells. Their glucose-stimulated insulin production remained much lower than that of natural human beta cells.
The transplant experiment in diabetic mice
Researchers transplanted the converted cells beneath the kidney capsule of mice with streptozotocin-induced diabetes. The cells lowered the animals’ blood glucose to near-normal levels for six weeks. This result came from a mouse model, following experiments with cultured cells.
What the preclinical result means
The findings do not show that a person’s pancreas can be made to produce more insulin through ALDH3B2 loss of function, or that the approach treats diabetes in people. The work describes a laboratory route for giving pancreatic duct cells some beta-cell characteristics, followed by a glucose-lowering result in mice.
Further research needs to clarify how ALDH3B2 influences duct-cell identity and how it could be targeted selectively. ALDH3B2 is used by cells beyond the pancreatic ducts, making selective targeting an important research challenge.
